echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > No conformity evaluation has been carried out, and procurement of 64 drug enterprise varieties has been suspended

    No conformity evaluation has been carried out, and procurement of 64 drug enterprise varieties has been suspended

    • Last Update: 2019-02-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The announcement on suspending the qualification of online drug transaction of enterprises that fail to pass the conformity evaluation of quality and efficacy of generic drugs (hereinafter referred to as the announcement) was released by Heilongjiang provincial drug centralized purchase network on Tuesday According to the announcement, there are three manufacturers (up to February 15, 2019) that have passed the conformity assessment of quality and efficacy of generic drugs due to four product specifications, i.e amoxicillin capsule (0.25g), escitalopram oxalate tablet (10mg), entecavir dispersible tablet (0.5mg), entecavir capsule (0.5mg), etc., and those who fail to pass the conformity assessment of quality and efficacy of generic drugs are suspended According to the simple statistics, 64 enterprises have been suspended from the network As we all know, Guangdong, Liaoning, Hunan, Jiangxi, Zhejiang, Heilongjiang and other provinces have held a non purchasing attitude towards the non evaluated products before, and Jiangxi, Heilongjiang, Guangxi and Jiangsu successively announced the suspension of the online qualification of the non evaluated drugs, with a total number of more than 50 drug regulations This is the second time for Heilongjiang to suspend the qualification of drug manufacturers without conformity assessment On November 22, 2018, Jiangsu public resources trading center issued the notice on publicizing the suspension of procurement of drugs failing to pass the quality and efficacy consistency evaluation of generic drugs According to the notice, nine drugs were suspended from purchasing, involving nine pharmaceutical companies On November 15, 2018, Guangxi pharmaceutical machinery centralized purchase network released the notice on suspending the qualification of online transaction of some drugs that failed to pass the consistency evaluation, and 9 drugs were suspended On December 4, 2018, Jiangxi Medical purchasing service center issued the notice of Jiangxi Province on adjusting the purchasing price and purchasing qualification of some products in 2018, 63 enterprises were suspended from purchasing qualification On November 5, 2018, Jiangxi pharmaceutical procurement service platform again issued the notice on adjusting the qualification of online procurement of some drugs, suspending the procurement of three product specifications of two pharmaceutical companies, because the same reason was that they failed to pass the consistency evaluation On August 11 and August 17, 2018, Jiangxi pharmaceutical purchasing service platform issued two notices successively As there are 3 manufacturers that have passed the consistency evaluation for some products, 6 products of 6 enterprises have been suspended from the Internet and are not allowed to participate in online purchasing On October 26, 2018, Hubei provincial public hospital drug (consumables) supply assurance comprehensive management network issued the notice on adjusting the information of online listing of failed conformity evaluation varieties, 5 failed conformity evaluation varieties were suspended from online listing, involving 14 drugs from 10 production enterprises On October 18, 2018, Heilongjiang Provincial Health and Health Commission issued the announcement on suspending the qualification of online trading of drugs (the first batch) of enterprises that failed to pass the conformity assessment of quality and efficacy of generic drugs 27 drugs were suspended from purchasing, involving 23 pharmaceutical companies In addition, 64 enterprises have suspended the online purchase qualification this time It can be predicted that those enterprises that have not evaluated drugs will face difficulties 12 products, 3 specifications According to the statistics of pharmaceutical intelligence data, up to now, there are totally 12 product specifications, among which there are 6 enterprises that have reviewed amlodipine besylate tablets, 4 enterprises that have reviewed 7 varieties of rosuvastatin calcium tablets, tenofovir dipivoxil fumarate tablets, entecavir dispersible tablets, entecavir capsules, montmorillonite powder, cefuroxime dipivoxil tablets and Amoxicillin Capsules See the following table for more details: Attachment: information reference of drugs (Heilongjiang) failing to pass the quality and efficacy consistency evaluation of generic drugs: yaozhiwang, saibailan, Heilongjiang drug centralized purchase network
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.